Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 100,000 shares of the business’s stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $89.48, for a total value of $8,948,000.00. Following the completion of the sale, the director directly owned 501,477 shares of the company’s stock, valued at $44,872,161.96. The trade was a 16.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Liquidia Stock Down 0.3%
LQDA stock traded down $0.26 during trading on Tuesday, reaching $84.16. 276,611 shares of the stock were exchanged, compared to its average volume of 1,803,461. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $16.82 and a twelve month high of $91.10. The firm’s 50 day moving average is $71.77 and its 200 day moving average is $50.58. The firm has a market cap of $7.48 billion, a P/E ratio of 604.11 and a beta of 0.55.
Liquidia (NASDAQ:LQDA – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, research analysts forecast that Liquidia Corporation will post 3.02 EPS for the current year.
Institutional Trading of Liquidia
Wall Street Analyst Weigh In
Several research firms have recently commented on LQDA. Raymond James Financial reissued a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Royal Bank Of Canada set a $130.00 price objective on Liquidia in a report on Friday. HC Wainwright set a $36.00 price objective on Liquidia in a research note on Friday. Finally, Wells Fargo & Company increased their price objective on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.18.
Read Our Latest Report on LQDA
About Liquidia
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Read More
- Five stocks we like better than Liquidia
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
- Whirlpool’s Report May Show How Frozen the Housing Market Really Is
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
